A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 986 in Healthy Subjects and Heart Failure Patients
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2017
At a glance
- Drugs AMG 986 (Primary) ; AMG 986 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Amgen
- 03 Nov 2017 Planned End Date changed from 20 Mar 2018 to 30 Jul 2018.
- 03 Nov 2017 Planned primary completion date changed from 20 Mar 2018 to 30 Jul 2018.
- 25 Nov 2016 New trial record